About Outlook Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://outlooktherapeutics.com/
Frequently Asked Questions
What is the 52-week range for OTLK?
The 52-week high is $2.5375 and the 52-week low is $0.1611.
What is the P/E ratio for OTLK?
The P/E ratio data is currently unavailable.
What is the dividend yield for OTLK?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -415.51%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -18156.22%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 31.58.
Analyst Recommendation Trends
Wall Street analyst consensus for OTLK over the last few months:
Latest OTLK News
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medic
Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. W
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Lundquist Kevin Michael | +500,000 | - | - |
| 2026-08-14 | Jahr Robert Charles | +151,515 | - | - |
| 2026-08-14 | Jahr Robert Charles | +151,515 | - | - |
| 2026-08-14 | KENYON LAWRENCE A | +101,010 | - | - |
| 2026-08-14 | KENYON LAWRENCE A | +101,010 | - | - |
| 2026-08-12 | Sukhtian Ghiath M. | +2,525,252 | - | - |
| 2026-08-12 | Sukhtian Ghiath M. | +2,525,252 | $0.99 | $2,499,999 |
| 2026-07-29 | Sukhtian Faisal Ghiath | +95,398 | $1.0482 | $99,996 |
| 2026-07-21 | Jahr Robert Charles | +100,000 | - | - |
| 2026-07-21 | KENYON LAWRENCE A | +210,078 | - | - |
| 2026-06-02 | Haddadin Yezan Munther | +29,000 | $0.8326 | $24,145 |
| 2026-05-28 | Sukhtian Ghiath M. | +8,571,428 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | -8,571,428 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | +3,458,571 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | -3,458,571 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | +3,458,571 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | -3,458,571 | - | - |
| 2026-05-28 | Sukhtian Ghiath M. | +8,539,709 | $0.5855 | $5,000,000 |
| 2026-05-27 | Sukhtian Faisal Ghiath | +122,174 | $0.4093 | $50,006 |
| 2026-05-26 | Haddadin Yezan Munther | +34,000 | $0.44 | $14,960 |
| 2026-05-26 | THURMAN RANDY H | +5,000 | $0.429 | $2,145 |
| 2026-05-26 | HILZINGER KURT J | +400,000 | $0.4413 | $176,520 |